multiple myeloma
Conditions
Interventions
Gold Standard:Clinical outcome
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. 18 years or above; 2. Patients with newly diagnosed multiple myeloma or primary plasma cell leukemia according to IMWG diagnostic criteria; 3. Female subjects of childbearing age must have a negative urine / blood pregnancy test within 7 days before cell therapy, female or male subjects of childbearing age need to take effective contraception throughout the study; 4. The patient volunteered to participate in the study, and he or his legal guardian signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who were treated or relapsed; 2. Patients who have been newly diagnosed with other primary cancers within the last 3 years that can affect the treatment or prognosis of multiple myeloma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early Mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Minimal residual disease;Amplification of 1q21;EQ-5D-5L;Prophylactic use of antibiotics;Biochemical recurrence’s intervention;Overall survival;Progression-free survival;adverse events ( AEs >= 3 );Overall response rate;Duration of response; | — |
Countries
China
Contacts
Public ContactJin Fengyan
The First Hospital of Jilin University
Outcome results
None listed